These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 26664141)

  • 1. The relationship between UGT1A1 gene polymorphism and irinotecan effect on extensive-stage small-cell lung cancer.
    Xiao XG; Xia S; Zou M; Mei Q; Zhou L; Wang SJ; Chen Y
    Onco Targets Ther; 2015; 8():3575-83. PubMed ID: 26664141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical significance of UGT1A1 gene polymorphisms on irinotecan-based regimens as the treatment in metastatic colorectal cancer.
    Li M; Wang Z; Guo J; Liu J; Li C; Liu L; Shi H; Liu L; Li H; Xie C; Zhang X; Sun W; Fang S; Bi X
    Onco Targets Ther; 2014; 7():1653-61. PubMed ID: 25285015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. UGT1A1 Gene Polymorphisms in Patients with Small Cell Lung Cancer Treated with Irinotecan-Platinum Doublet Chemotherapy and Their Association with Gastrointestinal Toxicity and Overall Survival.
    Bandyopadhyay A; Sharma S; Behera D; Singh N
    Oncologist; 2021 Aug; 26(8):701-713. PubMed ID: 33728696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. UGT1A1 predicts outcome in colorectal cancer treated with irinotecan and fluorouracil.
    Wang Y; Shen L; Xu N; Wang JW; Jiao SC; Liu ZY; Xu JM
    World J Gastroenterol; 2012 Dec; 18(45):6635-44. PubMed ID: 23236239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation between UGT1A1 gene polymorphism and irinotecan chemotherapy in metastatic colorectal cancer: a study from Guangxi Zhuang.
    Chen S; Hua L; Feng C; Mo Q; Wei M; Shen Y; Lin Z; Li G; Xu J; Guo C; Huang H
    BMC Gastroenterol; 2020 Apr; 20(1):96. PubMed ID: 32264830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Relationship between UGT1A1 gene polymorphisms and irinotecan-induced severe adverse events].
    Wang XF; Ma C; Gong FF; Yi SY; Xing GC; Wang KJ; Yang Q; Cao W
    Zhonghua Zhong Liu Za Zhi; 2018 Aug; 40(8):594-599. PubMed ID: 30139029
    [No Abstract]   [Full Text] [Related]  

  • 7. [Correlation between nUGT1A1 gene polymorphisms and adverse events of irinotecan plus S-1 for patients with recurrent or metastatic esophageal squamous cell carcinoma: a prospective, open-label, randomized controlled trial (ESWN 01)].
    Wang X; Liu Y; Huang JX; Lu P; Ba Y; Wu L; Bai YX; Zhang S; Feng JF; Cheng Y; Li J; Wen L; Yuan XL; Ma CW; Hu CH; Fan QX; Xu BH; Huang J
    Zhonghua Zhong Liu Za Zhi; 2021 Nov; 43(11):1177-1182. PubMed ID: 34794220
    [No Abstract]   [Full Text] [Related]  

  • 8. Distribution of uridine diphosphate glucuronosyltransferase 1A polymorphisms and their role in irinotecan-induced toxicity in patients with cancer.
    Wang Y; Yi C; Wang Y; Li H; Li B; Wang D; Du J; Liu L; Wang X
    Oncol Lett; 2017 Nov; 14(5):5743-5752. PubMed ID: 29113203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. UGT1A1 Gene Polymorphism Predicts Irinotecan-Induced Severe Neutropenia and Diarrhea in Chinese Cancer Patients.
    Peng H; Duan Z; Pan D; Wen J; Wei X
    Clin Lab; 2017 Sep; 63(9):1339-1346. PubMed ID: 28879724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between
    Bai Y; Wu HW; Ma X; Liu Y; Zhang YH
    Onco Targets Ther; 2017; 10():3071-3081. PubMed ID: 28790841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Uridine diphosphate glucuronide transferase 1A1FNx0128 gene polymorphism and the toxicity of irinotecan in recurrent and refractory small cell lung cancer.
    Yun F; Lulu M; Zhiyu H; Lei G; Haifeng Y; Tao L; Haiyan Y; Conghua X
    J Cancer Res Ther; 2014 Nov; 10 Suppl():C195-200. PubMed ID: 25450281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. UGT1A1 gene polymorphism: impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer.
    Schulz C; Heinemann V; Schalhorn A; Moosmann N; Zwingers T; Boeck S; Giessen C; Stemmler HJ
    World J Gastroenterol; 2009 Oct; 15(40):5058-66. PubMed ID: 19859999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cisplatin combined with irinotecan or etoposide for untreated extensive-stage small cell lung cancer: A multicenter randomized controlled clinical trial.
    Shi Y; Hu Y; Hu X; Li X; Lin L; Han X
    Thorac Cancer; 2015 Nov; 6(6):785-91. PubMed ID: 26557919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Association of UGT1A1 (*28, *60 and * 93) polymorphism with the adverse reactions of irinotecan chemotherapy in extensive stage small cell lung cancer].
    Ma L; Chen Y; Yang C; Jiang H; Zhu J; Cheng Y
    Zhonghua Zhong Liu Za Zhi; 2015 Jan; 37(1):29-32. PubMed ID: 25877315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Weekly regimen of irinotecan/docetaxel in previously treated non-small cell lung cancer patients and correlation with uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism.
    Font A; Sánchez JM; Tarón M; Martinez-Balibrea E; Sánchez JJ; Manzano JL; Margelí M; Richardet M; Barnadas A; Abad A; Rosell R
    Invest New Drugs; 2003 Nov; 21(4):435-43. PubMed ID: 14586211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma.
    Liu CY; Chen PM; Chiou TJ; Liu JH; Lin JK; Lin TC; Chen WS; Jiang JK; Wang HS; Wang WS
    Cancer; 2008 May; 112(9):1932-40. PubMed ID: 18300238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Individual Irinotecan Therapy Under the Guidance of Pre-Treated
    Lv H; Nie C; He Y; Chen B; Liu Y; Zhang J; Chen X
    Technol Cancer Res Treat; 2024; 23():15330338241236658. PubMed ID: 38497131
    [No Abstract]   [Full Text] [Related]  

  • 18. Predictive Value of UGT1A1*28 Polymorphism In Irinotecan-based Chemotherapy.
    Liu XH; Lu J; Duan W; Dai ZM; Wang M; Lin S; Yang PT; Tian T; Liu K; Zhu YY; Zheng Y; Sheng QW; Dai ZJ
    J Cancer; 2017; 8(4):691-703. PubMed ID: 28367249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Study on the Optimal Dose of Irinotecan for Patients with Heterozygous Uridine Diphosphate-Glucuronosyltransferase 1A1 (UGT1A1).
    Konaka K; Sakurada T; Saito T; Mori S; Imanishi M; Kakiuchi S; Fushitani S; Ishizawa K
    Biol Pharm Bull; 2019; 42(11):1839-1845. PubMed ID: 31685767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of nephrotoxicity during platinum-etoposide doublet therapy with UGT1A1 polymorphisms in small cell lung cancer patients.
    Anai S; Iwama E; Yoneshima Y; Otsubo K; Tanaka K; Nakanishi Y; Okamoto I
    Lung Cancer; 2018 Dec; 126():156-161. PubMed ID: 30527181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.